Company Overview
Snapshot
Founded in November 2020 by Jordan Pollack and Ben Friesem, VeinWay operates with 1-10 employees. The company has raised $7.43 million across 4 funding rounds. In September 2023, VeinWay closed an oversubscribed SAFE round and initiated a Series A round, with participation from Boston Scientific.
Business overview
VeinWay is a medical technology company focused on developing innovative solutions for crossing chronically occluded veins. Its core product, Traversa, is a dedicated device designed for venous recanalization, aiming to improve outcomes and facilitate endovascular procedures for chronic venous occlusions (CVOs). The company serves interventional radiologists and vascular surgeons, operating within the Health Tech & Life Sciences sector, specifically in Medical Devices and Medical Treatment & Therapeutics.
Strategic signal
In May 2024, VeinWay announced plans to commence a 30-patient trial to support FDA clearance and initial commercialization of its Traversa device by the end of 2024. This signals a critical step towards regulatory approval and market entry, indicating significant progress in bringing its novel venous recanalization technology to patients and validating its potential for growth in the venous disease market.
Log in to access full profile ›Company Intelligence Q&A
- What is VeinWay's primary product?
- VeinWay's primary product is Traversa, a novel catheter designed to safely and efficiently cross chronic blockages in veins, specifically targeting chronic venous occlusions (CVOs).
- When did VeinWay close its oversubscribed SAFE round and begin its Series A round?
- In September 2023, VeinWay closed an oversubscribed SAFE round and began its Series A round. This funding was intended to support design verification testing and preparation for the company's First-in-Human clinical trial of the Traversa system.
- Which investors participated in VeinWay's September 2023 SAFE round?
- The September 2023 SAFE round saw participation from Boston Scientific.
- What clinical milestones is VeinWay pursuing for its Traversa device?
- In May 2024, VeinWay announced plans to start a 30-patient trial to support FDA clearance and initial commercialization efforts for its Traversa device by the end of 2024. The device has already been used successfully in seven compassionate-use cases.
- What was VeinWay's involvement with MEDX Xelerator?
- VeinWay was formed in December 2020 as part of the MEDX Xelerator's X Lab program, which supports entrepreneurs in developing early-stage ideas for unmet clinical needs. In May 2021, VeinWay received a grant from MEDX Xelerator and the Israel Innovation Authority.